RCS - Frontier IP Group - Frontier IP announces stake in DiaGen

Frontier IPAnnouncement

02/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240502:nRSB9021Ma&default-theme=true

RNS Number : 9021M  Frontier IP Group plc  02 May 2024

REACH: non-regulatory announcement*

 

AIM: FIPP

2 May 2024

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Frontier IP announces stake in DiaGen

 

Frontier IP, a specialist in commercialising intellectual property, today
announces:

 

·    that the Group holds a 4.26 per cent stake in DiaGen Ai Inc
("DiaGen"), a Canadian company focused on AI-driven protein and peptide design
for medical applications

 

·    and that DiaGen has entered into a Technology Evaluation Agreement
with the Group's portfolio company The Vaccine Group ("TVG")

 

Frontier IP gained a stake in DiaGen, formerly known as Proteic Bioscience
Inc, in return for advisory services. DiaGen was founded in 2021 to develop a
proprietary AI engine for protein design, drug discovery and diagnostics for
health, wellness, longevity, and precision medicine.

 

This collaboration between DiaGen and TVG will bring together complimentary
approaches to developing novel and better vaccines for use in animals. Initial
focus will be on broadly-protective vaccine candidates for a disease caused by
a virus which mutates frequently, making it harder to develop effective
vaccines.

 

Paolo Lobo, DiaGen President, said: "We are excited to further iterate our
proprietary AI capabilities into a new addressable market in the Veterinary
sector to optimize the ideal protein structures for expression and immune
stimulation to complement TVG's experienced team in advancing their vaccine
pipeline."

 

TVG Chief Executive Jeremy Salt said: "The partnership with DiaGen will bring
strong complementary AI approaches to develop novel and improved vaccines.
TVG's herpesviral vector delivery system will be used to deliver optimal
antigens designed by DiaGen for expression in animal patients. Initial focus
will be on the development of broadly protective vaccine candidates for a
disease caused by a highly variable virus. This new partnership with DiaGen
represents a significant development in TVG's ability to address key gaps in
the veterinary vaccine market."

 

Frontier IP Chief Executive Neil Crabb said: "We have been working with DiaGen
for some time. The Technology Evaluation Agreement with TVG demonstrates the
benefits of our clusters approach, where expertise and know how can be shared
profitably between companies. I look forward to seeing the successful results
of this collaboration."

 

ENQUIRIES

                 Frontier IP Group Plc                                                   T: 020 7332 2338
                 Neil Crabb, Chief Executive                                             neil@frontierip.co.uk (mailto:neil@frontierip.co.uk)

                 Andrew Johnson, Communications and investor relations                   M: 07464 546 025

                 andrew.johnson@frontierip.co.uk

                 Company website: www.frontierip.co.uk (http://www.frontierip.co.uk/)
                 Allenby Capital Limited (Nominated Adviser)                             T: 0203 328 5656
                 Nick Athanas / George Payne

 DiaGen Ai Inc                                                                           ir@diagen.ai
 Brian Keane, CEO and Chair

 The Vaccine Group                                                                       Jeremy.salt@thevaccinegroup.co.uk
 Jeremy Salt, CEO

ABOUT FRONTIER IP

Frontier IP unites science, finance and industry by identifying strong
intellectual property and accelerating its development through a range of
commercialisation services. A critical part of the Group's work is involving
relevant industry partners at an early stage of development to ensure
technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence
income by taking an active involvement in spin-out companies, including
support for fund raising and collaboration with relevant industry partners at
an early stage of development.

* About Reach announcements

This is a RNS Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public domain.
Information required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an RNS
regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFSRESILIIS